Bio-Techne Management
Management Kriterienprüfungen 4/4
Bio-Techne CEO ist Kim Kelderman , ernannt in Feb 2024, hat eine Amtszeit von 2.25 Jahren. Die jährliche Gesamtvergütung beträgt $8.15M , bestehend aus 11.5% Gehalt und 88.5% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.042% der Aktien des Unternehmens, im Wert von $3.12M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 2.8 Jahre bzw. 6.9 Jahre.
Wichtige Informationen
Kim Kelderman
Geschäftsführender
US$8.2m
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | 11.48% |
| Amtszeit als Geschäftsführer | 2.3yrs |
| Eigentum des Geschäftsführers | 0.04% |
| Durchschnittliche Amtszeit des Managements | 2.8yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 6.9yrs |
Jüngste Management Updates
Recent updates
Analyse-Update • Apr 20
TECH: Spatial And Clinical Platforms Will Support Balanced Future Earnings Potential
Analysts have reset their price targets on Bio-Techne to $56.78 from $65.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Rolled out a new brand architecture that organizes offerings into three portfolio brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics.Analyse-Update • Apr 05
TECH: Clinical And Spatial Biology Platforms Will Support Higher Future Earnings Multiple
Analysts have trimmed their price target on Bio-Techne to about $65, with updated assumptions reflecting slightly adjusted discount rates, revenue growth expectations, profit margins, and a modest shift in projected future P/E levels. What's in the News Expanded COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits, plus updated HORIZON Image Analysis Software to support more flexible and sensitive tissue analysis workflows (Key Developments).Analyse-Update • Mar 22
TECH: Clinical Platform Adoption Will Support Higher Future Earnings Multiple
Analysts have lifted their price target on Bio-Techne to $65.41, citing updated assumptions that reflect slightly higher projected revenue growth, a modestly stronger profit margin, and a small adjustment to the discount rate and future P/E expectations. What's in the News Ella benchtop immunoassay platform receives CE-IVD marking and becomes available for clinical use in the European Union, supporting in-house test development, clinical trials, and translational activities on a validated platform (Key Developments).Analyse-Update • Mar 06
TECH: Multiomic Platform Expansion Will Support Higher Future Earnings Multiple
Analysts have raised their price target for Bio-Techne to $65.41 from $61.03, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple. What's in the News The Ella benchtop immunoassay platform received CE-IVD marking, making it available for clinical use in the European Union and positioning it as an option for in-house test development, clinical trials, and other translational activities (Key Developments).
Analyse-Update • Feb 20
TECH: Multiomic Platforms And 3D Workflows Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have adjusted their price target on Bio-Techne from $70.00 to $75.25, citing updated assumptions for revenue growth, profit margin, discount rate and future P/E that collectively support a higher assessed fair value. What’s in the News Ella benchtop immunoassay platform received CE-IVD marking and is now available for clinical use in the European Union.Analyseartikel • Feb 12
There May Be Some Bright Spots In Bio-Techne's (NASDAQ:TECH) Earnings
Shareholders appeared unconcerned with Bio-Techne Corporation's ( NASDAQ:TECH ) lackluster earnings report last week...Analyse-Update • Feb 05
TECH: Multiomic Platform Progress Will Contrast With Excessive Long Term Earnings Multiple
Analysts have lifted their fair value estimate for Bio-Techne by roughly $0.72 to reflect slightly stronger assumptions on revenue growth, profit margins, and the discount rate, along with a modestly lower future P/E. What's in the News Bio-Techne launched Cultrex Synthetic Hydrogel, a fully defined synthetic extracellular matrix aimed at more reproducible and scalable 3D stem cell and organoid research, reducing reliance on animal component derived matrices and supporting new approach methodologies in drug screening, toxicology, and personalized medicine (Key Developments).Analyse-Update • Jan 22
TECH: Multiomic Automation And Buybacks Will Support A Steady Forward Outlook
Narrative Update on Bio-Techne Analysts have nudged their fair value estimate for Bio-Techne to US$70.00 per share from about US$69.17, citing updated assumptions around discount rates, long term revenue growth, profit margins and future P/E expectations. What's in the News Spatial biology brand Lunaphore is partnering with the Wyss Center for Bio and Neuroengineering in Geneva to build an automated workflow for simultaneous RNA and protein detection in 3D specimens.Seeking Alpha • Jan 08
Bio-Techne: Recovery Likely Coming, But Is There Enough Re-Rating Potential?
Summary Bio-Techne faces near-term growth headwinds from challenges in academic and biotech research funding, but retains strong leverage to growing spatial biology, proteomics, and cell/gene therapy research activity. Margin pressures from past acquisitions are easing; exiting Exosome Diagnostics and productivity initiatives should drive operating leverage and margin improvement. I expect revenue growth to reaccelerate to high single digits by mid-year, but valuation remains stretched, with fair value seen in the $60s. I am shifting to a more cautious stance, as upside appears limited without a significant inflection in revenue or margin expansion. Read the full article on Seeking AlphaAnalyse-Update • Jan 08
TECH: Multiomic Partnerships And Automation Will Support A Steady Forward Outlook
Analysts have kept their fair value estimate for Bio-Techne steady at about US$69.17, with small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions driving a refined but directionally unchanged price target view. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, targeting higher resolution multiomic analysis in intact samples and broader use of spatial biology tools in research and diagnostics (Key Developments).Analyse-Update • Dec 16
TECH: Multiomic Expansion And Margin Improvement Will Support Balanced Future Outlook
Analysts have raised their price target on Bio-Techne from approximately 53 dollars to about 60 dollars, citing expectations for modestly faster revenue growth, improving profit margins, and a higher justified future price to earnings multiple. What's in the News Bio-Techne's Lunaphore brand and the Wyss Center for Bio and Neuroengineering in Geneva are collaborating to develop an automated workflow for simultaneous RNA and protein detection in 3D specimens, aiming to extend multiomic spatial biology from 2D into 3D and reduce reliance on animal models (Key Developments).Analyse-Update • Dec 01
TECH: Share Buyback Completion And New Partnerships Will Maintain Steady Outlook
Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.Analyse-Update • Nov 17
TECH: Share Buyback Momentum Will Drive Stronger Performance Ahead
Narrative Update on Bio-Techne Analysts have increased their price target for Bio-Techne from $67.83 to $69.17, citing improved revenue growth and higher projected profit margins as key drivers behind the upward adjustment. What's in the News Bio-Techne successfully repurchased 500,000 shares between July and September 2025, completing a $124.06 million buyback under its May 2025 program (Buyback Tranche Update).Analyseartikel • Nov 08
Bio-Techne Corporation (NASDAQ:TECH) Just Released Its First-Quarter Earnings: Here's What Analysts Think
Bio-Techne Corporation ( NASDAQ:TECH ) shareholders are probably feeling a little disappointed, since its shares fell...Analyse-Update • Nov 03
TECH: Product Advances And Index Changes Will Influence Future Demand For Precision Tools
Analysts have nudged their price target for Bio-Techne higher, raising it by $0.75 to $67.83. They cite modest improvements in profitability expectations and a slightly increased fair value assessment.Analyse-Update • Oct 20
Chronic Disease Trends And Precision Medicine Will Shape Demand
Narrative Update on Bio-Techne Analysts have raised their price target for Bio-Techne from $66.23 to $67.08. This change reflects modest improvements in profit margin expectations, even though revenue growth forecasts have been slightly reduced.Analyse-Update • Aug 27
Chronic Disease Trends And Precision Medicine Will Shape Demand
Bio-Techne's consensus price target saw only a minimal increase to $65.31, as both future P/E and revenue growth forecasts remained largely unchanged. What's in the News Bio-Techne formed a strategic partnership to distribute Spear Bio's ultrasensitive immunoassays, enabling detection of low-abundance biomarkers in neurology, initially focusing on translational research in Alzheimer's disease.Analyseartikel • Jul 28
Investors Still Waiting For A Pull Back In Bio-Techne Corporation (NASDAQ:TECH)
Bio-Techne Corporation's ( NASDAQ:TECH ) price-to-earnings (or "P/E") ratio of 70x might make it look like a strong...Analyseartikel • May 29
What Does Bio-Techne Corporation's (NASDAQ:TECH) Share Price Indicate?
Bio-Techne Corporation ( NASDAQ:TECH ), might not be a large cap stock, but it saw significant share price movement...Seeking Alpha • Feb 27
Bio-Techne: Attractive Markets And A Good Moat, But Valuation Is Seldom A Bargain
Summary Bio-Techne's shares have been pressured lately on concerns about the academic research market and biopharma R&D restructuring, but core business trends look largely intact. Fiscal Q2 showed revenue growth of 9%, with strength in both Protein Sciences and Diagnostics & Spatial Biology, with notable gains in spatial biology and cell therapy reagents. Academic research funding cuts may impact Bio-Techne to some extent, but its core consumables are essential and less price-sensitive, mitigating significant revenue loss. Bio-Techne is well-positioned for where biopharma wants to direct its R&D budgets, including biologics, cell/gene therapy, bioproduction, and process automation. Valuation has long been a sticking point with Bio-Techne shares; I can't call 8x forward revenue "cheap", but it's about as cheap as the shares get and the business remains on a good trajectory. Read the full article on Seeking Alpha
Neue Analyse • Aug 22
Innovations In Molecular Diagnostics And Decisive Focus On Growth Verticals Promise Revenue Surge Amid Challenges
Bio-Techne's investment in advanced diagnostics and specialized instruments like Leo suggests strong potential for revenue growth from increased sales and market adoption.Analyse der Geschäftsführervergütung
| Datum | Gesamtvergütung | Gehalt | Unternehmensgewinne |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$109m |
| Dec 31 2025 | n/a | n/a | US$81m |
| Sep 30 2025 | n/a | n/a | US$78m |
| Jun 30 2025 | US$8m | US$936k | US$73m |
| Mar 31 2025 | n/a | n/a | US$132m |
| Dec 31 2024 | n/a | n/a | US$158m |
| Sep 30 2024 | n/a | n/a | US$151m |
| Jun 30 2024 | US$7m | US$760k | US$168m |
| Mar 31 2024 | n/a | n/a | US$203m |
| Dec 31 2023 | n/a | n/a | US$224m |
| Sep 30 2023 | n/a | n/a | US$247m |
| Jun 30 2023 | US$3m | US$590k | US$285m |
| Mar 31 2023 | n/a | n/a | US$271m |
| Dec 31 2022 | n/a | n/a | US$262m |
| Sep 30 2022 | n/a | n/a | US$292m |
| Jun 30 2022 | US$3m | US$562k | US$272m |
| Mar 31 2022 | n/a | n/a | US$225m |
| Dec 31 2021 | n/a | n/a | US$210m |
| Sep 30 2021 | n/a | n/a | US$177m |
| Jun 30 2021 | US$4m | US$530k | US$140m |
| Mar 31 2021 | n/a | n/a | US$184m |
| Dec 31 2020 | n/a | n/a | US$175m |
| Sep 30 2020 | n/a | n/a | US$248m |
| Jun 30 2020 | US$2m | US$500k | US$229m |
| Mar 31 2020 | n/a | n/a | US$187m |
| Dec 31 2019 | n/a | n/a | US$195m |
| Sep 30 2019 | n/a | n/a | US$93m |
| Jun 30 2019 | US$2m | US$452k | US$96m |
Vergütung im Vergleich zum Markt: KimDie Gesamtvergütung ($USD8.15M) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD8.41M).
Entschädigung vs. Einkommen: KimDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.
Geschäftsführer
Kim Kelderman (57 yo)
2.3yrs
Amtszeit
US$8,151,180
Vergütung
Mr. Kim Kelderman is Director of Biorez, Inc. from 2025. Mr. Kelderman is Director of CONMED Corporation from September 8, 2025. Mr. Kelderman serves as Director of SLMP, LLC since November 2021.He served...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 2.3yrs | US$8.15m | 0.042% $ 3.1m | |
| Executive VP of Finance & CFO | 12.1yrs | US$7.03m | 0.098% $ 7.3m | |
| Senior VP | 3.2yrs | US$1.98m | 0.0046% $ 343.8k | |
| President of Protein Sciences Segment | 4.3yrs | US$3.14m | 0.013% $ 972.6k | |
| VP & CTO | 2.3yrs | keine Daten | keine Daten | |
| VP of Investor Relations & Corporate Development | no data | keine Daten | keine Daten | |
| Vice President of Sales and Marketing | no data | keine Daten | keine Daten | |
| Senior Vice President of Strategy & Corporate Development | 2.3yrs | keine Daten | keine Daten | |
| Senior VP & Chief Human Resources Officer | 1.7yrs | keine Daten | keine Daten | |
| Managing Director | 9.8yrs | keine Daten | keine Daten | |
| President of Diagnostics and Spatial Biology Segment | 3.3yrs | keine Daten | 0.0040% $ 300.7k | |
| Senior Vice President of Bio-Techne Diagnostics Division | 2.3yrs | keine Daten | keine Daten |
2.8yrs
Durchschnittliche Betriebszugehörigkeit
54yo
Durchschnittliches Alter
Erfahrenes Management: TECHDas Führungsteam des Unternehmens gilt als erfahren (2.8 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| CEO, President & Director | 3.3yrs | US$8.15m | 0.042% $ 3.1m | |
| Independent Chairman of the Board | 23.3yrs | US$400.42k | 0.030% $ 2.2m | |
| Independent Director | 17yrs | US$300.42k | 0.043% $ 3.2m | |
| Independent Director | 9.3yrs | US$275.42k | 0.0098% $ 730.6k | |
| Independent Director | 5.8yrs | US$292.92k | 0.0056% $ 415.8k | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 9.3yrs | US$285.42k | 0.0098% $ 730.6k | |
| Independent Director | 1.3yrs | US$181.36k | 0.0018% $ 136.6k | |
| Member of Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Independent Director | 2.1yrs | US$275.35k | 0.0024% $ 179.7k | |
| Independent Director | 6.9yrs | US$275.42k | 0.0070% $ 521.2k |
6.9yrs
Durchschnittliche Betriebszugehörigkeit
62yo
Durchschnittliches Alter
Erfahrener Vorstand: TECHDie Vorstandsmitglieder gelten als erfahren (6.9 Jahre durchschnittliche Amtszeit).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/12 23:46 |
| Aktienkurs zum Tagesende | 2026/05/12 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/06/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Bio-Techne Corporation wird von 25 Analysten beobachtet. 12 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Toung | Argus Research Company |
| Catherine Ramsey Schulte | Baird |
| Robert Wasserman | Benchmark Company |